ArticleThe Journal of clinical investigation1998
Enhanced in vitro potency and in vivo immunogenicity of a CTL epitope from hepatitis C virus core protein following amino acid replacement at secondary HLA-A2.1 binding positions.
Article in The Journal of clinical investigation, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 95 citations in OpenAlex.
- EnhancedJournal of virology · 2022Article
- Production and immunogenicity of different prophylactic vaccines for hepatitis C virus (Review).Experimental and therapeutic medicine · 2022Review
- Neoantigens as potential vaccines in hepatocellular carcinoma.Journal for immunotherapy of cancer · 2022Article
- Identification of HLA class I-restricted immunogenic neoantigens in triple negative breast cancer.Frontiers in immunology · 2022Article
- Cancer vaccine strategies: translation from mice to human clinical trials.Cancer immunology, immunotherapy : CII · 2018Review
- TARP vaccination is associated with slowing in PSA velocity and decreasing tumor growth rates in patients with Stage D0 prostate cancer.Oncoimmunology · 2016Article
- Immune responses induced in HHD mice by multiepitope HIV vaccine based on cryptic epitope modification.Molecular biology reports · 2013Article
- Review
- Strategies to use immune modulators in therapeutic vaccines against cancer.Seminars in oncology · 2012Review
- Synergistic enhancement of CD8+ T cell-mediated tumor vaccine efficacy by an anti-transforming growth factor-beta monoclonal antibody.Clinical cancer research : an official journal of the American Association for Cancer Research · 2009Article
- Side-chain conformational space analysis (SCSA): a multi conformation-based QSAR approach for modeling and prediction of protein-peptide binding affinities.Journal of computer-aided molecular design · 2009Article
- Availability of a diversely avid CD8+ T cell repertoire specific for the subdominant HLA-A2-restricted HIV-1 Gag p2419-27 epitope.Journal of immunology (Baltimore, Md. : 1950) · 2007Article
- Possible therapeutic vaccine strategy against human immunodeficiency virus escape from reverse transcriptase inhibitors studied in HLA-A2 transgenic mice.Journal of virology · 2006Article
- The use of reverse immunology to identify HLA-A2 binding epitopes in Tie-2.Cancer immunology, immunotherapy : CII · 2006Article
- Identification of secernin 1 as a novel immunotherapy target for gastric cancer using the expression profiles of cDNA microarray.Cancer science · 2006Article
- Multiple costimulatory modalities enhance CTL avidity.Journal of immunology (Baltimore, Md. : 1950) · 2005Article
- Article
- Cellular immune responses in seronegative sexual contacts of acute hepatitis C patients.Journal of virology · 2004Article
- Progress on new vaccine strategies against chronic viral infections.The Journal of clinical investigation · 2004Review
- Protection against lethal vaccinia virus challenge in HLA-A2 transgenic mice by immunization with a single CD8+ T-cell peptide epitope of vaccinia and variola viruses.Journal of virology · 2004Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
Since the natural immune response to hepatitis C virus (HCV) is often unable to clear the infection, to enhance immunogenicity we studied substituted peptides from an HCV cytotoxic T lymphocyte (CTL) epitope (C7A2) from a conserved region of the HCV core protein (DLMGYIPLV) recognized by CTL lines from HLA-A2.1(+) HCV-infected patients and HLA-A2.1 transgenic mice. HLA-A2.1 binding, human and murine CTL recognition, and in vivo immunogenicity (using mice transgenic for human HLA-A2 in lieu of immunizing humans) were analyzed to define peptides with enhanced immunogenicity. Peptides substituted at position 1 showed enhanced HLA-A2 binding affinity, but paradoxically poorer immunogenicity. A peptide with Ala substituted at position 8 (8A) showed higher HLA-A2 binding affinity and CTL recognition and was a more potent in vivo immunogen in HLA-A2-transgenic mice, inducing higher CTL responses with higher avidity against native C7A2 than induced by C7A2 itself. These results suggest that peptide 8A is a more potent in vitro antigen and in vivo immunogen than C7A2 and may be useful as a vaccine component. They provide proof of principle that the strategy of epitope enhancement can enhance immunogenicity of a CTL epitope recognized by human CTL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.